Amyloidosis – short review

Agnieszka Gaczkowska, Paweł P. Jagodziński, Adrianna Mostowska

Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland

ABSTRACT

Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type. Systemic monoclonal immunoglobulin light-chain (AL) is the most common form of systemic amyloidosis. Systemic AA amyloidosis is associated with chronic inflammation or infective diseases and is the second common form of systemic amyloidosis. The golden standard in diagnosis of amyloidosis is biopsy. The model of treatment depends of type of amyloidosis. In some cases cell transplantation can be considered. In AA the purpose is to decrease inflammation.

Keywords: amyloidosis, amyloid, diagnostic, treatment.

Types of amyloidosis

Systemic monoclonal immunoglobulin light-chain (primary type AL) is the most common form of systemic amyloidosis. It is characterized by systemic disease (primary amyloidosis, multiple myeloma, Waldenstrom’s lymphoma) and local disease (skin, urinary tract, larynx, eyes). Onset of the disease may result in non-specific symptoms. This may be enlargement of the spleen or liver, edema (proteinuria, hypoalbuminemia, congestive heart failure), peripheral sensory neuropathy, carpal tunnel syndrome, diarrhoea, constipation (autonomic dysfunction), orthostatic hypotension, symptoms of cardiomyopathy (50% of patients), enlarged tongue, in appearance of blood around the eyes, nail dystrophy. In radiographic manifestations of systemic amyloidosis we can identify parenchymal findings: reticular nodular opacities, reticular opacities and diffuse alveolar opacities. Primary systemic amyloidosis can involve the kidneys, gastrointestinal tract, skin, respiratory system, heart, and other organs. However, there are known forms of localized amyloidosis affecting only one organ. The prognosis for patients is bad since this disease is rapidly progressive, affects multiple organs and median survival is 5 months from diagnosis [2, 4,
There are also extremely rare types of amyloidosis: with heavy chains (AH) and heavy and light chains (AHL), both included in the Ig-related amyloidosis. All described cases of AHL had renal involvement, patients are less likely to suffer from cardiac type and there was better patient survival than with AL [12, 19].

Systemic AA amyloidosis (known also as reactive or secondary) is associated with chronic inflammation or infective diseases. It is the second common form of systemic amyloidosis and it is popular in Europe and in developing countries (30–40% of renal cases). Patients with AA are usual younger than those with AL. High risk factors of AA are: arthritis – the common reason, hereditary periodic fevers, inflammatory bowel diseases, chronic infections (e.g. chronic cutaneous ulcers and osteomyelitis), immunodeficiency states, systemic vasculitis, neoplasia, tuberculosis and sarcoidosis. Clinical signs usually involve urinal system, including proteinuria in 95% and nephrotic syndrome in more than 50% of cases. Other common symptoms are massive splenomegaly, functional hyposplenism, amyloid deposits at the adrenal glands, liver and gastrointestinal tract. Cardiac and neuropathic symptoms are extremely uncommon [10–13]. AA type is caused by reactant protein serum amyloid A (SAA). SAA is synthesized under the cytokine control and it can increase in acute injury, infection or inflammation. There are two isoforms of SAA – SAA1 and SAA2. AA can be a serious complication for patients with the hereditary periodic fever syndromes: familial Mediterranean fever, the TRAPS syndrome, Muckle-Wells syndrome, and hyperimmunoglobulinemia IgD with periodic fever syndrome [32–34].

The hereditary amyloidosis is a rare group of disorders. It is mainly inherited as autosomal-dominant disorder. The most common type of familial amyloidosis is transthyretin amyloidosis (ATTR), but we can recognise other types with proteins including fibrinogen Aα chain (AFib), lysozyme (ALys), apolipoproteins AI (AApo AI) and AII (AApo AII), and gelsolin (AGel) [13–16]. ATTR includes five phenotypes: familial amyloid polyneuropathy type I or II, familial amyloid cardiomyopathy, familial oculoleptomeningeal amyloidosis and familial leptomeningeal amyloidosis. It can be presented as peripheral neuropathy, autonomic neuropathy, cardiomyopathy and ophthalmopathy. The amyloid-producing pathway is associated with mutations in the amyloid-β domain. The mutations of Alzheimer amyloid precursor protein are associated with the systemic hereditary amyloidosis [22–31]. To date, more than 90 single nucleotide variants have been identified in the coding sequence of TTR (OMIM *176300) in individuals with this type of amyloidosis. Familial ATTR amyloidosis is inherited in an autosomal dominant manner. Prenatal diagnosis is offered to all pregnant women if the pathogenic TTR variant has been identified in their families [25].

| Type                                | Symbol | The most common symptoms                                                                 | Therapy                                                                 |
|-------------------------------------|--------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Primary type                        | AL     | Systemic or local disease: enlargement of the spleen and liver, neuropathy, cardiomyopathy | High-dose alkylator-based chemotherapy, stem cell transplantation, diuresis, serial thoracenteses, pleurodesis, bronchial repermeabilization |
| Secondary/reactive type             | AA     | Diseases of urinal system – proteinuria, splenomegaly, functional hyposplenism, amyloid deposits at the adrenal glands, liver and gastrointestinal tract | Immunosuppressants, colchicine, demethyl sulfoxide, immunotherapy        |
| The hereditary types, the most common - transthyretin amyloidosis | ATTR (transthyretin amyloidosis) AFib (fibrinogen Aα chain) ALys (lysozyme) AApo Al (apolipoproteins Al) AApo All (apolipoproteins All) AGel (gelsolin) | Peripheral neuropathy, autonomic neuropathy, cardiomyopathy, ophthalmopathy | Early liver transplantation, possibility of hepatorenal or hepatocardiac transplantation |
| Dialysis-related/β2-microglobulin type | DRA    | Carpal tunnel syndrome, bone cysts, destructive arthropathies, spondylarthropathies         | Renal transplantation, hemodialysis with high-flux membranes and β2-microglobulin adsorption columns, steroids, non steroidal anti-inflammatory drugs |
| Senile systemic type                | SSA    | Heart failure, atrial arrhythmias and cardiomegaly                                         | Drugs therapy (diuretics, beta blockers, angiotensin enzyme inhibitors, angiotensin receptor blockers, digoxin), ventricular assist devices, heart transplantation |

Table 1. Amyloidosis review. The Table is based on articles cited in the text
Dialysis-related amyloidosis (DRA) is caused by deposition of β₂-microglobulin (β2M) in tissues during long-term dialysis in chronic kidney disease patients. The clinical sings include carpal tunnel syndrome – the most characteristic symptom, bone cysts, destructive arthropathies, spondylarthropathies and sometimes involve other organs like skin, liver, heart or spleen. Risk factors of DRA are: age, duration of dialysis, use of low-flux dialysis membrane and genetic factors, e.g. apolipoprotein alleles, which are correlated with Alzheimer disease. The genetic risk is the highest in the case of mutation in apolipoprotein ε4 allele [17, 18, 55, 59].

Senile systemic amyloidosis (SSA) is associated with elderly patients. This type of disease causes deposition of wild-type transthyretin molecules in myocardium and results in heart failure, atrial arrhythmias and cardiomegaly. The renal symptoms are rare. The prognosis is better than for patients with AL and it is usually few years of survival [19–21].

Diagnostic

The most frequent and the earliest sign in AA type is proteinuria leading to nephrotic syndrome. The only test, which can confirm amyloidosis is biopsy with histological demonstration of amyloid deposits [14]. Congo-red-positive biopsies observed with polarization microscopy are the golden standard in detecting the disease. Amyloid material can be recognised also by gentian violet or thioflavin T [35]. The good method to diagnose a systemic amyloidosis is the subcutaneous adipose tissue biopsy. This is of value in the AL, AA and ATTR, but it has some limitations: unequally distributed deposits, overstaining in Congo red samples with needle biopsies and relatively little involvement of subcutaneous fat tissue in some types of amyloidosis [36]. There are four techniques in typing of amyloid: immunohistochemistry, immunochemistry, mass spectrometry and chemistry. There are 14 proteins detected in samples of amyloidosis, which can be analysed by proteomics. These tests give the investigation of amyloidogenic protein precursors, the identification of the fibrillar deposited proteins, the characterization of the metabolic modifications in affected tissues and the detection of new biomarkers. Amyloid can be classified by antibodies, for example against amyloid P component, AA amyloid, apolipoprotein A-I, lyzosyme, fibrinogen, transthyretin and κ and λ light chains. The immunohistology is most useful for AA and ATTR. The mass spectrometry detects serum monoclonal immunoglobulin free light chains, which are secreted by plasma cells and circulate in plasma and it is useful in AL amyloidosis [37–40].

Treatment

The model of treatment depends on type of amyloidosis. At the 13th International Symposium on Amyloidosis in Groningen updated criteria were given which defined treatment for individual involved organs. The most important is early diagnosis and effective therapy [41].

Treatment of AL is individualized and determined by age, organ dysfunction, present biomarkers and cardiac response. One of the oldest methods is high-dose alkylator-based chemotherapy. It was melphalan with prednisone, later substituted for dexamethasone. Another options are thalidomide, lenalidomide, pomalidomide, bortezomib and colchicine. In some cases autologous stem cell transplantation with earlier chemotherapy has higher response rate than conventional chemotherapy. This method is the standard treatment for multiple myeloma and employed for AL. Medical treatment is also prescribed according to clinical indications and medical judgement and it includes diuresis, serial thoracenteses, pleurodesis, bronchial repermeabilization, avoid digitalis and calcium channel blockers, assessment for atrial thrombi, mechanical pacing [41–44].

AA is associated with other diseases with inflammation and the basis is a common control of both diseases and decrease of the inflammation. The popular treatment is immunosuppressants: methotrexate, cyclophosphamide and chlorambucil. In some diseases, for example familial Mediterranean fever, the most effective drug is colchicine. The best prognostic factor of therapy is normal renal function. Another effective treatment is demethyl sulfoxide, especially in bowel’s inflammatory diseases. There are tested new methods of immunotherapy, which may eliminate deposits from systemic and local amyloidosis [45–50].

In ATTR type the best option is early liver transplantation. The surgery can not prevent all symptoms, cardiomyopathy and neuropathy progress even after transplantation. In cases with advanced organ’s damage there is possibility of hepatorenal or hepatocardiatic transplantation [51, 52].

For patients with DRA the most important step is renal transplantation, which reduces β₂-microglobulin to the normal level in plasma. The surgery does not decrease radiologic and histologic lesions long time after transplantation. β₂-microglobulin can be removed by hemodialysis with high-flux membranes and
Acknowledgements

Conflict of interest statement
The authors declare no conflict of interest.

Funding sources
There are no sources of funding to declare.

References
1. Berk JL, O’Regan A, Skinner M. Pulmonary and Tracheobronchial Amyloidosis. Semin Respir Crit Care. 2002;23(2):155–165.
2. Chu H, Zhao L, Zhang Z, Gui T, Yi X, Sun X. Clinical characteristics of amyloidosis with isolated respiratory system involvement: A review of 13 cases. Ann Thorac Med. 2012;7:243–249.
3. Berrando J, Novella L, Sanz F, Lluch R, de Casimiro E, Lloret T. Management of Tracheobronchial Amyloidosis With Therapeutic Bronchoscopic Techniques. Arch Bronconeumol. 2013;49(5):207–209.
4. Finocchiaro G, Merlo M, Pinamonti B, Barbati G, Santarossa E, Dolmo S, et al. Long term survival in patients with cardiac amyloidosis. Prevalence and characterisation during follow-up. Heart Lung. 2013;22:647–654.
5. Lee AY, Godwin JD, Pipavath SNJ. Case 182: Pulmonary Amyloidosis. Radiology. 2012;263:929–932.
6. Kyle, R. A. Amyloidosis: a convoluted story. British Journal of Haematology, 114: 529–538.
7. F. Chiti, C. M. Dobson, Protein Misfolding, Functional Amyloid, and Human Disease. Annu. Rev. Biochem. 2006;75, 333–366.
8. Westermark P, Bergström J, Solomon A, et al. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003;10 Suppl 1:48.
9. Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83:463–70.
10. Pinney JH, Lachmann HJ. Systemic AA amyloidosis. Subcell Biochem. 2012;65:541.
11. Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepsys MB (1998) SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 5:262–265.
12. Scarpioni R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoimmune inflammatory diseases and the role of inflammatory β2-microglobulin adsorption columns. The established DRA can be treated with low-dose steroids and non steroidal anti-inflammatory drugs [53–55].
13. Khalbighi, Mazdak A., W. Dean Wallace, and Miguel F. Palma-Diaz. “Amyloid Nephropathy.” Clinical Kidney Journal 7.2 (2014):97–106. PMC. Web. 14 Mar. 2016.
14. Real de Asia, Diego et al. Systemic AA Amyloidosis: Epidemiology, Diagnosis, and Management. Clinical Epide- miology 6 (2014):369–377. PMC. Web. 14 Mar. 2016.
15. Sekijima Y, Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):1036–43.
16. Sekijima Y, Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy. Rinsho Shinkeigaku. 2014;54(12):953–6.
17. Schiff, H. (2014). Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodialysis International, 18: 136–141.
18. Yamamoto S, Gejyo F, Historical background and clinical treatment of dialysis-related amyloidosis. Biochim Biophys Acta. 2005 Nov 10;1753(1):4–10.
19. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile Systemic Amyloidosis Presenting With Heart Failure: A Comparison With Light Chain–Associated Amyloidosis. Arch Intern Med. 2005;165(12):1425–1429.
20. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. Circulation. 2016;133:282–290.
21. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K, Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003 Aug;10 Suppl 1:48–54.
22. Sahlin, C., Lord, A., Magnusson, K., Englund, H., Almeida, C. G., Greengard, P., et al. (2007), The Arctic Alzheimer mutation favors intracellular amyloid-β production by making amyloid precursor protein less available to α-secretase. Journal of Neurochemistry, 101: 854–862.
23. Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehniert A, et al. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science. 1990 Jun 1;248(4959):1120–2.
24. Levy E1, Prellic F, Frangione B. Studies on the first described Alzheimer’s disease amyloid beta mutant, the Dutch variant. J Alzheimers Dis. 2006;9(3 Suppl):329–39.
25. Connors LH, Richardson AM, Théberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000 Mar;7(1):54–69.
26. Annamalai, K., Gührs, K.-H., Koehler, R., Schmidt, M., Michel, H., Loos, C., et al. (2016), Polymorphism of Amyloid Fibrils In Vivo. Angew. Chem. Int. Ed.
27. Prusiner, Stanley B. Biology and Genetics of Prions Cau- sing Neurodegeneration. Annual review of genetics 47 (2013):601–623. PMC. Web. 15 Mar. 2016.
28. Gregorini G, Izzl C, Obici I, Tardanico R, Röcken C, Vio- la BF, et al. Renal apolipoprotein A-1 amyloidosis: a rare and usually ignored cause of hereditary tubulo-interstitial nephritis. J Am Soc Nephrol. 2005 Dec;16(12):3680–6. Epub. 2005 Oct 12.

Amyloidosis – short review
29. Said, S, et al. Renal Amyloidosis: Origin and Clinical-pathologic Correlations of 474 Recent Cases. Clinical Journal of the American Society of Nephrology: CJASN 8(9) (2013):1515–1523. PMC. Web. 15 Mar. 2016.

30. Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN. Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood. 2010 May 27;115(21):4313; author reply. 4314–5.

31. Rostagno, A. et al. “Cerebral Amyloidosis: Amyloid Subunits, Mutants and Phenotypes.” Cellular and molecular life sciences: CMLS 67(4) (2010):581–600. PMC. Web. 15 Mar. 2016.

32. Obici, L., Raimondi, S., Lavatelli, F., Bellotti, V. and Merlino, G. (2009). Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis & Rheumatism, 61: 1435–1440.

33. Frame, N. M. and Gursky, O. (2016). Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Letters. doi: 10.1002/1873-3468.12116.

34. Lane, T., Loeffler, J. M., Rowczenio, D. M., Gilbertson, J. A., Bybee, A., Russell, T. L., et al. (2013). Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. Arthritis & Rheumatism, 65:1116–1121. doi: 10.1002/art.37827.

35. Howie AJ, Brewer DB. Optical properties of amyloid stained by Congo red: history and mechanisms. Micron. 2009;40(3):285–301.

36. Westernmark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid. 2011 Dec;18(4):175–6. doi: 10.3109/13506129.2011.631270.

37. Brambilla, F., Lavatelli, F., Merlini, G. and Mauri, P. (2013), Clinical proteomics for diagnosis and typing of systemic amyloidoses. Prot. Clin. Appl., 7: 136–143. doi: 10.1002/prca.201200097.

38. Linke RP. On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012 Aug;47(2):61–132. doi: 10.1016/j.progch.2012.03.001.

39. Mikhailova LM, Gioeva ZV, Rëken K. Histological and immunohistochemical examinations in the diagnosis of hepatic amyloidosis. Arkh Patol. 2015 Jul-Aug;77(4):1–6.

40. Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med. 2016 Feb 4. pii: /j/cclm.ahead-of-print/cclm-2015–0917/cclm-2015–0917.xml. doi: 10.1515/cclm-2015–0917. [Epub ahead of print]

41. Merlini, Giampaolo, David C. Seldin, and Morie A. Gertz. “Amyloidosis: Pathogenesis and New Therapeutic Options.” Journal of Clinical Oncology 29.14 (2011):1924–1933. PMC. Web. 15 Mar. 2016.

42. Moreau, P., Leblond, V., Bourquinel, P., Facon, T., Huynh, A., Caillot, D., et al. (1998). Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101: 766–769. doi: 10.1046/j.1365–2141.1998.00772.x

43. Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, et al. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. Int J Hematol. 2016 Mar;103(3):299–305. doi: 10.1007/s12185–015–1922-x. Epub. 2015 Dec 24.

44. Hayashi T, Ikeda H, Igarashi T, Maruyama Y, Aoki Y, Nojima M, et al. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. Int J Hematol. 2014 Dec;100(6):554–8. doi: 10.1007/s12185–014–1680–1. Epub. 2014 Oct 4.

45. Ortiz-Santamaria V, Olivé A, Valls-Roc M, Tena X. Treatment of AA amyloid with chlorambucil. Rheumatology (Oxford). 2002 Jul;41(7):833.

46. Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cyto-static therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford). 2003 Feb;42(2):362–6.

47. Hamanoue S, Suwabe T, Hoshino J, Sumida K, Mise K, Hayami N, et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2015 Jan 25:1–4. [Epub ahead of print]

48. Ikawari R, Sakemi T, Fujimoto K. Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn’s disease. Gastroenterology. 1999 Oct;117(4):1031–2.

49. Bodin, K. “Antibodies to Human Serum Amyloid P Component Eliminate Visceral Amyloid Deposits.” Nature 468.7320 (2010):93–97. PMC. Web. 15 Mar. 2016.

50. Sakoto, T. “Target Mediated Drug Disposition Model of CPHC in Patients with Systemic Amyloidosis.” CPT: Pharmacometrics & Systems Pharmacology 4.2 (2015): e15. PMC. Web. 15 Mar. 2016.

51. Ando Y. Effect of liver transplantation on familial amyloidotic polyneuropathy (FAP) and its limit. Rinsho Shinkigaku. 2011 Nov;51(11):1138–41.

52. Nelson LM, Pennina L, Sander K, Hansen PB, Villadsen GE, Rasmussen A, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic polyneuropathy. Amyloid. 2011 Dec;18(4):175–6. doi: 10.1080/13506129.2011.631270.

53. Brambilla, F., Lavatelli, F., Merlini, G. and Mauri, P. (2013), Clinical proteomics for diagnosis and typing of systemic amyloidoses. Prot. Clin. Appl., 7: 136–143. doi: 10.1002/prca.201200097.

54. Linke RP. On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012 Aug;47(2):61–132. doi: 10.1016/j.progch.2012.03.001.

55. Mikhailova LM, Gioeva ZV, Rikken K. Histological and immunohistochemical examinations in the diagnosis of hepatic amyloidosis. Arkh Patol. 2015 Jul-Aug;77(4):1–6.

56. Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med. 2016 Feb 4. pii: /j/ccm. ahead-of-print/ccm-2015–0917/ccm-2015–0917.xml. doi: 10.1515/ccm-2015–0917. [Epub ahead of print]

57. Merlino, Giampaolo, David C. Seldin, and Morie A. Gertz. “Amyloidosis: Pathogenesis and New Therapeutic Options.” Journal of Clinical Oncology 29.14 (2011):1924–1933. PMC. Web. 15 Mar. 2016.

58. Moreau, P., Leblond, V., Bourquinel, P., Facon, T., Huynh, A., Caillot, D., et al. (1998). Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101: 766–769. doi: 10.1046/j.1365–2141.1998.00772.x
Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20;116(21):2420–6. Epub. 2007 Nov 5.

Nelson, Peter T. et al. “APOE-2 and APOE-4 Correlate with Increased Amyloid Accumulation in Cerebral Vasculature.” Journal of neuropathology and experimental neurology 72.7 (2013):708–715. PMC. Web. 29 Mar. 2016.

Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. 8 ed. Vol 4. New York, NY: McGraw-Hill; 2001:5345–78.

Correspondence address:
Agnieszka Gaczkowska, MD
Poznan University of Medical Sciences
Department of Biochemistry and Molecular Biology
6 Swiecickiego St, 60-781 Poznan, Poland
phone: +48618546511
fax: +48618546510
email: gaczka@gmail.com

Acceptance for editing: 2016-06-29
Acceptance for publication: 2016-06-30